← Back to Search

Neurostimulation Device

Patient open label intervention arm for Cystic Fibrosis

N/A
Waitlist Available
Research Sponsored by St. Louis University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-4 weeks and 4-8 weeks
Awards & highlights

Summary

This trial tests a small, non-invasive device called IB-Stim that sends mild electrical signals to reduce abdominal pain in children with Cystic Fibrosis. The device works by stimulating a nerve that helps control pain, aiming to improve their quality of life.

Eligible Conditions
  • Cystic Fibrosis
  • Irritable Bowel Syndrome
  • Chronic Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-4 weeks and 4-8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-4 weeks and 4-8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Therapeutic procedure
Hypesthesia
To determine whether PENFS therapy improves abdominal pain and IBS-symptom severity in CF.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patient open label intervention armExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
194 Previous Clinical Trials
43,645 Total Patients Enrolled
1 Trials studying Cystic Fibrosis
3 Patients Enrolled for Cystic Fibrosis
Washington University School of MedicineOTHER
1,949 Previous Clinical Trials
2,307,557 Total Patients Enrolled
5 Trials studying Cystic Fibrosis
251 Patients Enrolled for Cystic Fibrosis
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top